nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—PSMB5—coronary artery disease	0.258	0.918	CbGaD
Bortezomib—Nateglinide—Trandolapril—coronary artery disease	0.0397	0.145	CrCrCtD
Bortezomib—Nateglinide—Enalapril—coronary artery disease	0.0397	0.145	CrCrCtD
Bortezomib—Aspartame—Trandolapril—coronary artery disease	0.0377	0.138	CrCrCtD
Bortezomib—Aspartame—Enalapril—coronary artery disease	0.0377	0.138	CrCrCtD
Bortezomib—Nateglinide—Lisinopril—coronary artery disease	0.0311	0.113	CrCrCtD
Bortezomib—Nateglinide—Ramipril—coronary artery disease	0.0301	0.11	CrCrCtD
Bortezomib—Aspartame—Lisinopril—coronary artery disease	0.0295	0.108	CrCrCtD
Bortezomib—Aspartame—Ramipril—coronary artery disease	0.0286	0.104	CrCrCtD
Bortezomib—CYP2C19—coronary artery disease	0.0231	0.0822	CbGaD
Bortezomib—CYP2C8—Fenofibrate—coronary artery disease	0.0104	0.0467	CbGbCtD
Bortezomib—CYP2C8—Gemfibrozil—coronary artery disease	0.00833	0.0373	CbGbCtD
Bortezomib—PTGS1—Acetylsalicylic acid—coronary artery disease	0.00786	0.0352	CbGbCtD
Bortezomib—CYP2C9—Fenofibrate—coronary artery disease	0.00727	0.0326	CbGbCtD
Bortezomib—CYP2C8—Clopidogrel—coronary artery disease	0.00722	0.0324	CbGbCtD
Bortezomib—CYP2C19—Gemfibrozil—coronary artery disease	0.00699	0.0313	CbGbCtD
Bortezomib—CYP1A2—Gemfibrozil—coronary artery disease	0.00645	0.0289	CbGbCtD
Bortezomib—CYP2C8—Pitavastatin—coronary artery disease	0.00631	0.0283	CbGbCtD
Bortezomib—CYP2C19—Clopidogrel—coronary artery disease	0.00606	0.0271	CbGbCtD
Bortezomib—CYP2C9—Gemfibrozil—coronary artery disease	0.00581	0.026	CbGbCtD
Bortezomib—CYP1A2—Clopidogrel—coronary artery disease	0.00559	0.025	CbGbCtD
Bortezomib—CYP2C19—Telmisartan—coronary artery disease	0.0053	0.0237	CbGbCtD
Bortezomib—CYP2C9—Clopidogrel—coronary artery disease	0.00504	0.0226	CbGbCtD
Bortezomib—CYP3A4—Ticagrelor—coronary artery disease	0.00474	0.0212	CbGbCtD
Bortezomib—CYP2C8—Acetylsalicylic acid—coronary artery disease	0.00454	0.0203	CbGbCtD
Bortezomib—CYP2C9—Pitavastatin—coronary artery disease	0.0044	0.0197	CbGbCtD
Bortezomib—CYP2C8—Simvastatin—coronary artery disease	0.00433	0.0194	CbGbCtD
Bortezomib—CYP2C9—Valsartan—coronary artery disease	0.00428	0.0192	CbGbCtD
Bortezomib—CYP2C19—Timolol—coronary artery disease	0.00427	0.0191	CbGbCtD
Bortezomib—CYP2C8—Pravastatin—coronary artery disease	0.00423	0.019	CbGbCtD
Bortezomib—CYP2C8—Lovastatin—coronary artery disease	0.00423	0.019	CbGbCtD
Bortezomib—CYP3A4—Fenofibrate—coronary artery disease	0.00423	0.0189	CbGbCtD
Bortezomib—CYP2C19—Rosuvastatin—coronary artery disease	0.0039	0.0175	CbGbCtD
Bortezomib—CYP2C8—Atorvastatin—coronary artery disease	0.00386	0.0173	CbGbCtD
Bortezomib—CYP2C19—Acetylsalicylic acid—coronary artery disease	0.0038	0.017	CbGbCtD
Bortezomib—CYP2C19—Simvastatin—coronary artery disease	0.00363	0.0163	CbGbCtD
Bortezomib—CYP2C19—Lovastatin—coronary artery disease	0.00355	0.0159	CbGbCtD
Bortezomib—CYP2C8—Losartan—coronary artery disease	0.00353	0.0158	CbGbCtD
Bortezomib—CYP2D6—Niacin—coronary artery disease	0.00349	0.0156	CbGbCtD
Bortezomib—CYP3A4—Gemfibrozil—coronary artery disease	0.00338	0.0151	CbGbCtD
Bortezomib—CYP2C9—Rosuvastatin—coronary artery disease	0.00325	0.0145	CbGbCtD
Bortezomib—CYP2D6—Timolol—coronary artery disease	0.00325	0.0145	CbGbCtD
Bortezomib—CYP2C19—Atorvastatin—coronary artery disease	0.00324	0.0145	CbGbCtD
Bortezomib—CYP2C9—Acetylsalicylic acid—coronary artery disease	0.00316	0.0142	CbGbCtD
Bortezomib—CYP2C9—Simvastatin—coronary artery disease	0.00302	0.0135	CbGbCtD
Bortezomib—CYP2C19—Losartan—coronary artery disease	0.00296	0.0133	CbGbCtD
Bortezomib—CYP2C9—Pravastatin—coronary artery disease	0.00295	0.0132	CbGbCtD
Bortezomib—CYP2C9—Lovastatin—coronary artery disease	0.00295	0.0132	CbGbCtD
Bortezomib—CYP3A4—Clopidogrel—coronary artery disease	0.00293	0.0131	CbGbCtD
Bortezomib—CYP2D6—Captopril—coronary artery disease	0.00286	0.0128	CbGbCtD
Bortezomib—CYP2D6—Simvastatin—coronary artery disease	0.00276	0.0124	CbGbCtD
Bortezomib—CYP1A2—Losartan—coronary artery disease	0.00273	0.0122	CbGbCtD
Bortezomib—CYP3A4—Eplerenone—coronary artery disease	0.00272	0.0122	CbGbCtD
Bortezomib—CYP2D6—Pravastatin—coronary artery disease	0.0027	0.0121	CbGbCtD
Bortezomib—CYP2D6—Lovastatin—coronary artery disease	0.0027	0.0121	CbGbCtD
Bortezomib—CYP2C9—Atorvastatin—coronary artery disease	0.00269	0.0121	CbGbCtD
Bortezomib—CYP2C9—Losartan—coronary artery disease	0.00246	0.011	CbGbCtD
Bortezomib—CYP2D6—Atorvastatin—coronary artery disease	0.00246	0.011	CbGbCtD
Bortezomib—CYP3A4—Enalapril—coronary artery disease	0.00243	0.0109	CbGbCtD
Bortezomib—CYP2C9—cardial valve—coronary artery disease	0.00229	0.0775	CbGeAlD
Bortezomib—CYP3A4—Ezetimibe—coronary artery disease	0.00189	0.00846	CbGbCtD
Bortezomib—CYP3A4—Rosuvastatin—coronary artery disease	0.00189	0.00846	CbGbCtD
Bortezomib—CYP3A4—Simvastatin—coronary artery disease	0.00175	0.00786	CbGbCtD
Bortezomib—CYP3A4—Lovastatin—coronary artery disease	0.00172	0.00769	CbGbCtD
Bortezomib—CYP3A4—Pravastatin—coronary artery disease	0.00172	0.00769	CbGbCtD
Bortezomib—CYP3A4—Atorvastatin—coronary artery disease	0.00156	0.00701	CbGbCtD
Bortezomib—CYP3A4—Losartan—coronary artery disease	0.00143	0.00641	CbGbCtD
Bortezomib—CTSG—myocardium—coronary artery disease	0.0012	0.0406	CbGeAlD
Bortezomib—PSMD1—cardiac ventricle—coronary artery disease	0.00103	0.0348	CbGeAlD
Bortezomib—PSMD1—myocardium—coronary artery disease	0.000967	0.0327	CbGeAlD
Bortezomib—PSMD2—cardiac ventricle—coronary artery disease	0.000911	0.0308	CbGeAlD
Bortezomib—PSMD2—myocardium—coronary artery disease	0.000857	0.029	CbGeAlD
Bortezomib—CTSG—heart—coronary artery disease	0.000837	0.0283	CbGeAlD
Bortezomib—PSMA1—heart—coronary artery disease	0.000804	0.0272	CbGeAlD
Bortezomib—PSMB5—cardiac ventricle—coronary artery disease	0.0008	0.027	CbGeAlD
Bortezomib—CTSG—cardiovascular system—coronary artery disease	0.00079	0.0267	CbGeAlD
Bortezomib—PSMA1—cardiovascular system—coronary artery disease	0.000759	0.0256	CbGeAlD
Bortezomib—PSMB5—myocardium—coronary artery disease	0.000752	0.0254	CbGeAlD
Bortezomib—CTSG—cardiac atrium—coronary artery disease	0.000716	0.0242	CbGeAlD
Bortezomib—PSMB1—cardiac ventricle—coronary artery disease	0.000699	0.0236	CbGeAlD
Bortezomib—PSMB2—cardiac ventricle—coronary artery disease	0.000682	0.023	CbGeAlD
Bortezomib—PSMD1—heart—coronary artery disease	0.000675	0.0228	CbGeAlD
Bortezomib—PSMB1—myocardium—coronary artery disease	0.000657	0.0222	CbGeAlD
Bortezomib—PSMB2—myocardium—coronary artery disease	0.000641	0.0217	CbGeAlD
Bortezomib—CTSG—blood—coronary artery disease	0.000625	0.0211	CbGeAlD
Bortezomib—PSMD2—heart—coronary artery disease	0.000598	0.0202	CbGeAlD
Bortezomib—PSMB8—heart—coronary artery disease	0.000594	0.0201	CbGeAlD
Bortezomib—PSMD2—Pimozide—Ezetimibe—coronary artery disease	0.000583	0.381	CbGdCrCtD
Bortezomib—PSMD1—cardiac atrium—coronary artery disease	0.000577	0.0195	CbGeAlD
Bortezomib—Lacosamide—CA5B—coronary artery disease	0.000569	0.726	CrCbGaD
Bortezomib—PSMD2—cardiovascular system—coronary artery disease	0.000564	0.0191	CbGeAlD
Bortezomib—SLC31A1—myocardium—coronary artery disease	0.000555	0.0188	CbGeAlD
Bortezomib—PSMB5—heart—coronary artery disease	0.000525	0.0177	CbGeAlD
Bortezomib—PSMD2—cardiac atrium—coronary artery disease	0.000511	0.0173	CbGeAlD
Bortezomib—PSMD1—blood—coronary artery disease	0.000504	0.017	CbGeAlD
Bortezomib—PSMB1—heart—coronary artery disease	0.000459	0.0155	CbGeAlD
Bortezomib—PSMB5—cardiac atrium—coronary artery disease	0.000449	0.0152	CbGeAlD
Bortezomib—PSMB2—heart—coronary artery disease	0.000448	0.0151	CbGeAlD
Bortezomib—PSMD2—blood—coronary artery disease	0.000446	0.0151	CbGeAlD
Bortezomib—PSMB8—blood—coronary artery disease	0.000443	0.015	CbGeAlD
Bortezomib—PSMB1—cardiovascular system—coronary artery disease	0.000433	0.0146	CbGeAlD
Bortezomib—PSMB2—cardiovascular system—coronary artery disease	0.000422	0.0143	CbGeAlD
Bortezomib—PSMB1—cardiac atrium—coronary artery disease	0.000392	0.0133	CbGeAlD
Bortezomib—PSMB5—blood—coronary artery disease	0.000392	0.0132	CbGeAlD
Bortezomib—SLC31A1—heart—coronary artery disease	0.000388	0.0131	CbGeAlD
Bortezomib—PSMB2—cardiac atrium—coronary artery disease	0.000383	0.0129	CbGeAlD
Bortezomib—PSMB1—blood—coronary artery disease	0.000342	0.0116	CbGeAlD
Bortezomib—PSMB2—blood—coronary artery disease	0.000334	0.0113	CbGeAlD
Bortezomib—SLC31A1—cardiac atrium—coronary artery disease	0.000332	0.0112	CbGeAlD
Bortezomib—PSMB8—Fluvastatin—Pitavastatin—coronary artery disease	0.000322	0.21	CbGdCrCtD
Bortezomib—PTGS1—artery—coronary artery disease	0.000314	0.0106	CbGeAlD
Bortezomib—SLC31A1—blood—coronary artery disease	0.000289	0.00978	CbGeAlD
Bortezomib—PSMB8—Fluvastatin—Rosuvastatin—coronary artery disease	0.000287	0.188	CbGdCrCtD
Bortezomib—PTGS1—endothelium—coronary artery disease	0.000265	0.00897	CbGeAlD
Bortezomib—PSMB8—Fluvastatin—Atorvastatin—coronary artery disease	0.000244	0.159	CbGdCrCtD
Bortezomib—CYP1A1—cardiac ventricle—coronary artery disease	0.000201	0.00678	CbGeAlD
Bortezomib—PTGS1—myocardium—coronary artery disease	0.000166	0.0056	CbGeAlD
Bortezomib—Nateglinide—PPARG—coronary artery disease	0.000156	0.199	CrCbGaD
Bortezomib—CYP1A1—heart—coronary artery disease	0.000132	0.00445	CbGeAlD
Bortezomib—CYP2C9—heart—coronary artery disease	0.000127	0.00428	CbGeAlD
Bortezomib—CYP2C19—blood—coronary artery disease	0.000122	0.00412	CbGeAlD
Bortezomib—CYP2C9—cardiovascular system—coronary artery disease	0.00012	0.00404	CbGeAlD
Bortezomib—PTGS1—heart—coronary artery disease	0.000116	0.00391	CbGeAlD
Bortezomib—CYP1A1—cardiac atrium—coronary artery disease	0.000113	0.00381	CbGeAlD
Bortezomib—PTGS1—cardiovascular system—coronary artery disease	0.000109	0.00369	CbGeAlD
Bortezomib—CYP2C8—blood—coronary artery disease	0.000106	0.0036	CbGeAlD
Bortezomib—CYP1A2—blood—coronary artery disease	9.96e-05	0.00337	CbGeAlD
Bortezomib—PTGS1—cardiac atrium—coronary artery disease	9.89e-05	0.00334	CbGeAlD
Bortezomib—CYP1A1—blood—coronary artery disease	9.83e-05	0.00332	CbGeAlD
Bortezomib—PSMB8—Testosterone Propionate—Eplerenone—coronary artery disease	9.52e-05	0.0622	CbGdCrCtD
Bortezomib—CYP2C9—blood—coronary artery disease	9.46e-05	0.0032	CbGeAlD
Bortezomib—PTGS1—blood—coronary artery disease	8.63e-05	0.00292	CbGeAlD
Bortezomib—CYP3A4—blood—coronary artery disease	7.21e-05	0.00244	CbGeAlD
Bortezomib—CYP2D6—blood—coronary artery disease	7.1e-05	0.0024	CbGeAlD
Bortezomib—Nateglinide—ALB—coronary artery disease	5.87e-05	0.0748	CrCbGaD
Bortezomib—Confusional state—Ramipril—coronary artery disease	1.27e-05	0.000124	CcSEcCtD
Bortezomib—Discomfort—Timolol—coronary artery disease	1.27e-05	0.000123	CcSEcCtD
Bortezomib—Asthenia—Niacin—coronary artery disease	1.27e-05	0.000123	CcSEcCtD
Bortezomib—Fatigue—Losartan—coronary artery disease	1.26e-05	0.000123	CcSEcCtD
Bortezomib—Headache—Ezetimibe—coronary artery disease	1.26e-05	0.000123	CcSEcCtD
Bortezomib—Malaise—Lisinopril—coronary artery disease	1.26e-05	0.000123	CcSEcCtD
Bortezomib—Oedema—Ramipril—coronary artery disease	1.26e-05	0.000122	CcSEcCtD
Bortezomib—Anaphylactic shock—Ramipril—coronary artery disease	1.26e-05	0.000122	CcSEcCtD
Bortezomib—Vertigo—Lisinopril—coronary artery disease	1.26e-05	0.000122	CcSEcCtD
Bortezomib—Pain—Losartan—coronary artery disease	1.25e-05	0.000122	CcSEcCtD
Bortezomib—Constipation—Losartan—coronary artery disease	1.25e-05	0.000122	CcSEcCtD
Bortezomib—Syncope—Lisinopril—coronary artery disease	1.25e-05	0.000122	CcSEcCtD
Bortezomib—Vomiting—Eplerenone—coronary artery disease	1.25e-05	0.000122	CcSEcCtD
Bortezomib—Feeling abnormal—Furosemide—coronary artery disease	1.25e-05	0.000122	CcSEcCtD
Bortezomib—Leukopenia—Lisinopril—coronary artery disease	1.25e-05	0.000122	CcSEcCtD
Bortezomib—Nausea—Fenofibrate—coronary artery disease	1.25e-05	0.000122	CcSEcCtD
Bortezomib—Pruritus—Niacin—coronary artery disease	1.25e-05	0.000122	CcSEcCtD
Bortezomib—Asthenia—Pravastatin—coronary artery disease	1.25e-05	0.000121	CcSEcCtD
Bortezomib—Gastrointestinal pain—Furosemide—coronary artery disease	1.24e-05	0.000121	CcSEcCtD
Bortezomib—Rash—Eplerenone—coronary artery disease	1.24e-05	0.000121	CcSEcCtD
Bortezomib—Urticaria—Perindopril—coronary artery disease	1.24e-05	0.000121	CcSEcCtD
Bortezomib—Hypersensitivity—Trandolapril—coronary artery disease	1.24e-05	0.000121	CcSEcCtD
Bortezomib—Dermatitis—Eplerenone—coronary artery disease	1.24e-05	0.000121	CcSEcCtD
Bortezomib—Diarrhoea—Valsartan—coronary artery disease	1.24e-05	0.000121	CcSEcCtD
Bortezomib—Confusional state—Timolol—coronary artery disease	1.24e-05	0.000121	CcSEcCtD
Bortezomib—Shock—Ramipril—coronary artery disease	1.24e-05	0.000121	CcSEcCtD
Bortezomib—Hypersensitivity—Enalapril—coronary artery disease	1.24e-05	0.00012	CcSEcCtD
Bortezomib—Abdominal pain—Perindopril—coronary artery disease	1.24e-05	0.00012	CcSEcCtD
Bortezomib—Body temperature increased—Perindopril—coronary artery disease	1.24e-05	0.00012	CcSEcCtD
Bortezomib—Palpitations—Lisinopril—coronary artery disease	1.24e-05	0.00012	CcSEcCtD
Bortezomib—Diarrhoea—Olmesartan—coronary artery disease	1.24e-05	0.00012	CcSEcCtD
Bortezomib—Headache—Eplerenone—coronary artery disease	1.23e-05	0.00012	CcSEcCtD
Bortezomib—Nervous system disorder—Ramipril—coronary artery disease	1.23e-05	0.00012	CcSEcCtD
Bortezomib—Thrombocytopenia—Ramipril—coronary artery disease	1.23e-05	0.00012	CcSEcCtD
Bortezomib—Oedema—Timolol—coronary artery disease	1.23e-05	0.00012	CcSEcCtD
Bortezomib—Anaphylactic shock—Timolol—coronary artery disease	1.23e-05	0.00012	CcSEcCtD
Bortezomib—Pruritus—Pravastatin—coronary artery disease	1.23e-05	0.00012	CcSEcCtD
Bortezomib—Loss of consciousness—Lisinopril—coronary artery disease	1.23e-05	0.00012	CcSEcCtD
Bortezomib—Nausea—Clopidogrel—coronary artery disease	1.23e-05	0.00012	CcSEcCtD
Bortezomib—Tachycardia—Ramipril—coronary artery disease	1.23e-05	0.00012	CcSEcCtD
Bortezomib—Skin disorder—Ramipril—coronary artery disease	1.22e-05	0.000119	CcSEcCtD
Bortezomib—Infection—Timolol—coronary artery disease	1.22e-05	0.000119	CcSEcCtD
Bortezomib—Vomiting—Simvastatin—coronary artery disease	1.22e-05	0.000119	CcSEcCtD
Bortezomib—Hypersensitivity—Telmisartan—coronary artery disease	1.22e-05	0.000119	CcSEcCtD
Bortezomib—Cough—Lisinopril—coronary artery disease	1.22e-05	0.000119	CcSEcCtD
Bortezomib—Nausea—Lovastatin—coronary artery disease	1.22e-05	0.000119	CcSEcCtD
Bortezomib—Hyperhidrosis—Ramipril—coronary artery disease	1.22e-05	0.000118	CcSEcCtD
Bortezomib—Rash—Simvastatin—coronary artery disease	1.21e-05	0.000118	CcSEcCtD
Bortezomib—Dermatitis—Simvastatin—coronary artery disease	1.21e-05	0.000118	CcSEcCtD
Bortezomib—Asthenia—Trandolapril—coronary artery disease	1.21e-05	0.000118	CcSEcCtD
Bortezomib—Shock—Timolol—coronary artery disease	1.21e-05	0.000118	CcSEcCtD
Bortezomib—Feeling abnormal—Losartan—coronary artery disease	1.21e-05	0.000118	CcSEcCtD
Bortezomib—Urticaria—Furosemide—coronary artery disease	1.21e-05	0.000118	CcSEcCtD
Bortezomib—Diarrhoea—Niacin—coronary artery disease	1.21e-05	0.000118	CcSEcCtD
Bortezomib—Nervous system disorder—Timolol—coronary artery disease	1.21e-05	0.000117	CcSEcCtD
Bortezomib—Asthenia—Enalapril—coronary artery disease	1.2e-05	0.000117	CcSEcCtD
Bortezomib—Headache—Simvastatin—coronary artery disease	1.2e-05	0.000117	CcSEcCtD
Bortezomib—Abdominal pain—Furosemide—coronary artery disease	1.2e-05	0.000117	CcSEcCtD
Bortezomib—Body temperature increased—Furosemide—coronary artery disease	1.2e-05	0.000117	CcSEcCtD
Bortezomib—Gastrointestinal pain—Losartan—coronary artery disease	1.2e-05	0.000117	CcSEcCtD
Bortezomib—Dizziness—Valsartan—coronary artery disease	1.2e-05	0.000117	CcSEcCtD
Bortezomib—Anorexia—Ramipril—coronary artery disease	1.2e-05	0.000117	CcSEcCtD
Bortezomib—Nausea—Ezetimibe—coronary artery disease	1.2e-05	0.000116	CcSEcCtD
Bortezomib—Skin disorder—Timolol—coronary artery disease	1.19e-05	0.000116	CcSEcCtD
Bortezomib—Dizziness—Olmesartan—coronary artery disease	1.19e-05	0.000116	CcSEcCtD
Bortezomib—Pruritus—Trandolapril—coronary artery disease	1.19e-05	0.000116	CcSEcCtD
Bortezomib—Arthralgia—Lisinopril—coronary artery disease	1.19e-05	0.000116	CcSEcCtD
Bortezomib—Chest pain—Lisinopril—coronary artery disease	1.19e-05	0.000116	CcSEcCtD
Bortezomib—Myalgia—Lisinopril—coronary artery disease	1.19e-05	0.000116	CcSEcCtD
Bortezomib—Hyperhidrosis—Timolol—coronary artery disease	1.19e-05	0.000116	CcSEcCtD
Bortezomib—Asthenia—Telmisartan—coronary artery disease	1.19e-05	0.000116	CcSEcCtD
Bortezomib—Pruritus—Enalapril—coronary artery disease	1.19e-05	0.000116	CcSEcCtD
Bortezomib—Diarrhoea—Pravastatin—coronary artery disease	1.19e-05	0.000116	CcSEcCtD
Bortezomib—Anxiety—Lisinopril—coronary artery disease	1.19e-05	0.000115	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	1.18e-05	0.000115	CcSEcCtD
Bortezomib—Discomfort—Lisinopril—coronary artery disease	1.18e-05	0.000114	CcSEcCtD
Bortezomib—Hypotension—Ramipril—coronary artery disease	1.18e-05	0.000114	CcSEcCtD
Bortezomib—Anorexia—Timolol—coronary artery disease	1.17e-05	0.000114	CcSEcCtD
Bortezomib—Pruritus—Telmisartan—coronary artery disease	1.17e-05	0.000114	CcSEcCtD
Bortezomib—Nausea—Eplerenone—coronary artery disease	1.17e-05	0.000114	CcSEcCtD
Bortezomib—Dizziness—Niacin—coronary artery disease	1.17e-05	0.000114	CcSEcCtD
Bortezomib—Urticaria—Losartan—coronary artery disease	1.17e-05	0.000113	CcSEcCtD
Bortezomib—Abdominal pain—Losartan—coronary artery disease	1.16e-05	0.000113	CcSEcCtD
Bortezomib—Body temperature increased—Losartan—coronary artery disease	1.16e-05	0.000113	CcSEcCtD
Bortezomib—Asthenia—Captopril—coronary artery disease	1.16e-05	0.000113	CcSEcCtD
Bortezomib—Diarrhoea—Trandolapril—coronary artery disease	1.15e-05	0.000112	CcSEcCtD
Bortezomib—Vomiting—Valsartan—coronary artery disease	1.15e-05	0.000112	CcSEcCtD
Bortezomib—Confusional state—Lisinopril—coronary artery disease	1.15e-05	0.000112	CcSEcCtD
Bortezomib—Diarrhoea—Enalapril—coronary artery disease	1.15e-05	0.000112	CcSEcCtD
Bortezomib—Hypotension—Timolol—coronary artery disease	1.15e-05	0.000112	CcSEcCtD
Bortezomib—Dizziness—Pravastatin—coronary artery disease	1.15e-05	0.000112	CcSEcCtD
Bortezomib—Vomiting—Olmesartan—coronary artery disease	1.15e-05	0.000112	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Ramipril—coronary artery disease	1.15e-05	0.000112	CcSEcCtD
Bortezomib—Rash—Valsartan—coronary artery disease	1.14e-05	0.000111	CcSEcCtD
Bortezomib—Dermatitis—Valsartan—coronary artery disease	1.14e-05	0.000111	CcSEcCtD
Bortezomib—Nausea—Simvastatin—coronary artery disease	1.14e-05	0.000111	CcSEcCtD
Bortezomib—Oedema—Lisinopril—coronary artery disease	1.14e-05	0.000111	CcSEcCtD
Bortezomib—Anaphylactic shock—Lisinopril—coronary artery disease	1.14e-05	0.000111	CcSEcCtD
Bortezomib—Pruritus—Captopril—coronary artery disease	1.14e-05	0.000111	CcSEcCtD
Bortezomib—Rash—Olmesartan—coronary artery disease	1.14e-05	0.000111	CcSEcCtD
Bortezomib—Insomnia—Ramipril—coronary artery disease	1.14e-05	0.000111	CcSEcCtD
Bortezomib—Dermatitis—Olmesartan—coronary artery disease	1.14e-05	0.000111	CcSEcCtD
Bortezomib—Headache—Valsartan—coronary artery disease	1.14e-05	0.000111	CcSEcCtD
Bortezomib—Diarrhoea—Telmisartan—coronary artery disease	1.13e-05	0.00011	CcSEcCtD
Bortezomib—Infection—Lisinopril—coronary artery disease	1.13e-05	0.00011	CcSEcCtD
Bortezomib—Headache—Olmesartan—coronary artery disease	1.13e-05	0.00011	CcSEcCtD
Bortezomib—Paraesthesia—Ramipril—coronary artery disease	1.13e-05	0.00011	CcSEcCtD
Bortezomib—Shock—Lisinopril—coronary artery disease	1.12e-05	0.000109	CcSEcCtD
Bortezomib—Asthenia—Perindopril—coronary artery disease	1.12e-05	0.000109	CcSEcCtD
Bortezomib—Dyspnoea—Ramipril—coronary artery disease	1.12e-05	0.000109	CcSEcCtD
Bortezomib—Vomiting—Niacin—coronary artery disease	1.12e-05	0.000109	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Timolol—coronary artery disease	1.12e-05	0.000109	CcSEcCtD
Bortezomib—Hypersensitivity—Furosemide—coronary artery disease	1.12e-05	0.000109	CcSEcCtD
Bortezomib—Thrombocytopenia—Lisinopril—coronary artery disease	1.12e-05	0.000109	CcSEcCtD
Bortezomib—Dizziness—Trandolapril—coronary artery disease	1.12e-05	0.000109	CcSEcCtD
Bortezomib—Tachycardia—Lisinopril—coronary artery disease	1.11e-05	0.000108	CcSEcCtD
Bortezomib—Insomnia—Timolol—coronary artery disease	1.11e-05	0.000108	CcSEcCtD
Bortezomib—Rash—Niacin—coronary artery disease	1.11e-05	0.000108	CcSEcCtD
Bortezomib—Dermatitis—Niacin—coronary artery disease	1.11e-05	0.000108	CcSEcCtD
Bortezomib—Dizziness—Enalapril—coronary artery disease	1.11e-05	0.000108	CcSEcCtD
Bortezomib—Skin disorder—Lisinopril—coronary artery disease	1.11e-05	0.000108	CcSEcCtD
Bortezomib—Dyspepsia—Ramipril—coronary artery disease	1.11e-05	0.000108	CcSEcCtD
Bortezomib—Pruritus—Perindopril—coronary artery disease	1.11e-05	0.000108	CcSEcCtD
Bortezomib—Headache—Niacin—coronary artery disease	1.1e-05	0.000108	CcSEcCtD
Bortezomib—Paraesthesia—Timolol—coronary artery disease	1.1e-05	0.000108	CcSEcCtD
Bortezomib—Vomiting—Pravastatin—coronary artery disease	1.1e-05	0.000108	CcSEcCtD
Bortezomib—Hyperhidrosis—Lisinopril—coronary artery disease	1.1e-05	0.000107	CcSEcCtD
Bortezomib—Diarrhoea—Captopril—coronary artery disease	1.1e-05	0.000107	CcSEcCtD
Bortezomib—Dyspnoea—Timolol—coronary artery disease	1.1e-05	0.000107	CcSEcCtD
Bortezomib—Dizziness—Telmisartan—coronary artery disease	1.1e-05	0.000107	CcSEcCtD
Bortezomib—Rash—Pravastatin—coronary artery disease	1.09e-05	0.000107	CcSEcCtD
Bortezomib—Dermatitis—Pravastatin—coronary artery disease	1.09e-05	0.000107	CcSEcCtD
Bortezomib—Decreased appetite—Ramipril—coronary artery disease	1.09e-05	0.000106	CcSEcCtD
Bortezomib—Asthenia—Furosemide—coronary artery disease	1.09e-05	0.000106	CcSEcCtD
Bortezomib—Headache—Pravastatin—coronary artery disease	1.09e-05	0.000106	CcSEcCtD
Bortezomib—Anorexia—Lisinopril—coronary artery disease	1.09e-05	0.000106	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Ramipril—coronary artery disease	1.09e-05	0.000106	CcSEcCtD
Bortezomib—Fatigue—Ramipril—coronary artery disease	1.08e-05	0.000106	CcSEcCtD
Bortezomib—Dyspepsia—Timolol—coronary artery disease	1.08e-05	0.000105	CcSEcCtD
Bortezomib—Hypersensitivity—Losartan—coronary artery disease	1.08e-05	0.000105	CcSEcCtD
Bortezomib—Nausea—Valsartan—coronary artery disease	1.08e-05	0.000105	CcSEcCtD
Bortezomib—Pruritus—Furosemide—coronary artery disease	1.08e-05	0.000105	CcSEcCtD
Bortezomib—Constipation—Ramipril—coronary artery disease	1.08e-05	0.000105	CcSEcCtD
Bortezomib—Nausea—Olmesartan—coronary artery disease	1.07e-05	0.000104	CcSEcCtD
Bortezomib—Vomiting—Trandolapril—coronary artery disease	1.07e-05	0.000104	CcSEcCtD
Bortezomib—Diarrhoea—Perindopril—coronary artery disease	1.07e-05	0.000104	CcSEcCtD
Bortezomib—Decreased appetite—Timolol—coronary artery disease	1.07e-05	0.000104	CcSEcCtD
Bortezomib—Vomiting—Enalapril—coronary artery disease	1.07e-05	0.000104	CcSEcCtD
Bortezomib—Hypotension—Lisinopril—coronary artery disease	1.07e-05	0.000104	CcSEcCtD
Bortezomib—Dizziness—Captopril—coronary artery disease	1.07e-05	0.000104	CcSEcCtD
Bortezomib—Rash—Trandolapril—coronary artery disease	1.06e-05	0.000104	CcSEcCtD
Bortezomib—Dermatitis—Trandolapril—coronary artery disease	1.06e-05	0.000103	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Timolol—coronary artery disease	1.06e-05	0.000103	CcSEcCtD
Bortezomib—Fatigue—Timolol—coronary artery disease	1.06e-05	0.000103	CcSEcCtD
Bortezomib—Rash—Enalapril—coronary artery disease	1.06e-05	0.000103	CcSEcCtD
Bortezomib—Dermatitis—Enalapril—coronary artery disease	1.06e-05	0.000103	CcSEcCtD
Bortezomib—Headache—Trandolapril—coronary artery disease	1.06e-05	0.000103	CcSEcCtD
Bortezomib—Vomiting—Telmisartan—coronary artery disease	1.05e-05	0.000103	CcSEcCtD
Bortezomib—Asthenia—Losartan—coronary artery disease	1.05e-05	0.000102	CcSEcCtD
Bortezomib—Headache—Enalapril—coronary artery disease	1.05e-05	0.000102	CcSEcCtD
Bortezomib—Pain—Timolol—coronary artery disease	1.05e-05	0.000102	CcSEcCtD
Bortezomib—Nausea—Niacin—coronary artery disease	1.05e-05	0.000102	CcSEcCtD
Bortezomib—Rash—Telmisartan—coronary artery disease	1.04e-05	0.000102	CcSEcCtD
Bortezomib—Dermatitis—Telmisartan—coronary artery disease	1.04e-05	0.000102	CcSEcCtD
Bortezomib—Diarrhoea—Furosemide—coronary artery disease	1.04e-05	0.000101	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Lisinopril—coronary artery disease	1.04e-05	0.000101	CcSEcCtD
Bortezomib—Pruritus—Losartan—coronary artery disease	1.04e-05	0.000101	CcSEcCtD
Bortezomib—Headache—Telmisartan—coronary artery disease	1.04e-05	0.000101	CcSEcCtD
Bortezomib—Feeling abnormal—Ramipril—coronary artery disease	1.04e-05	0.000101	CcSEcCtD
Bortezomib—Dizziness—Perindopril—coronary artery disease	1.03e-05	0.000101	CcSEcCtD
Bortezomib—Insomnia—Lisinopril—coronary artery disease	1.03e-05	0.0001	CcSEcCtD
Bortezomib—Nausea—Pravastatin—coronary artery disease	1.03e-05	0.0001	CcSEcCtD
Bortezomib—Gastrointestinal pain—Ramipril—coronary artery disease	1.03e-05	0.0001	CcSEcCtD
Bortezomib—Paraesthesia—Lisinopril—coronary artery disease	1.02e-05	9.97e-05	CcSEcCtD
Bortezomib—Vomiting—Captopril—coronary artery disease	1.02e-05	9.97e-05	CcSEcCtD
Bortezomib—Dyspnoea—Lisinopril—coronary artery disease	1.02e-05	9.9e-05	CcSEcCtD
Bortezomib—Rash—Captopril—coronary artery disease	1.02e-05	9.89e-05	CcSEcCtD
Bortezomib—Dermatitis—Captopril—coronary artery disease	1.01e-05	9.88e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Timolol—coronary artery disease	1.01e-05	9.87e-05	CcSEcCtD
Bortezomib—Headache—Captopril—coronary artery disease	1.01e-05	9.83e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Timolol—coronary artery disease	1.01e-05	9.79e-05	CcSEcCtD
Bortezomib—Dizziness—Furosemide—coronary artery disease	1.01e-05	9.79e-05	CcSEcCtD
Bortezomib—Dyspepsia—Lisinopril—coronary artery disease	1e-05	9.78e-05	CcSEcCtD
Bortezomib—Diarrhoea—Losartan—coronary artery disease	1e-05	9.77e-05	CcSEcCtD
Bortezomib—Nausea—Trandolapril—coronary artery disease	1e-05	9.75e-05	CcSEcCtD
Bortezomib—Urticaria—Ramipril—coronary artery disease	9.99e-06	9.73e-05	CcSEcCtD
Bortezomib—Nausea—Enalapril—coronary artery disease	9.98e-06	9.71e-05	CcSEcCtD
Bortezomib—Vomiting—Perindopril—coronary artery disease	9.94e-06	9.68e-05	CcSEcCtD
Bortezomib—Abdominal pain—Ramipril—coronary artery disease	9.94e-06	9.68e-05	CcSEcCtD
Bortezomib—Body temperature increased—Ramipril—coronary artery disease	9.94e-06	9.68e-05	CcSEcCtD
Bortezomib—Decreased appetite—Lisinopril—coronary artery disease	9.92e-06	9.66e-05	CcSEcCtD
Bortezomib—Rash—Perindopril—coronary artery disease	9.86e-06	9.6e-05	CcSEcCtD
Bortezomib—Dermatitis—Perindopril—coronary artery disease	9.85e-06	9.59e-05	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Lisinopril—coronary artery disease	9.85e-06	9.59e-05	CcSEcCtD
Bortezomib—Nausea—Telmisartan—coronary artery disease	9.84e-06	9.58e-05	CcSEcCtD
Bortezomib—Fatigue—Lisinopril—coronary artery disease	9.83e-06	9.58e-05	CcSEcCtD
Bortezomib—Headache—Perindopril—coronary artery disease	9.8e-06	9.54e-05	CcSEcCtD
Bortezomib—Urticaria—Timolol—coronary artery disease	9.77e-06	9.51e-05	CcSEcCtD
Bortezomib—Constipation—Lisinopril—coronary artery disease	9.75e-06	9.5e-05	CcSEcCtD
Bortezomib—Pain—Lisinopril—coronary artery disease	9.75e-06	9.5e-05	CcSEcCtD
Bortezomib—Abdominal pain—Timolol—coronary artery disease	9.72e-06	9.47e-05	CcSEcCtD
Bortezomib—Body temperature increased—Timolol—coronary artery disease	9.72e-06	9.47e-05	CcSEcCtD
Bortezomib—Dizziness—Losartan—coronary artery disease	9.7e-06	9.45e-05	CcSEcCtD
Bortezomib—Vomiting—Furosemide—coronary artery disease	9.67e-06	9.41e-05	CcSEcCtD
Bortezomib—Rash—Furosemide—coronary artery disease	9.59e-06	9.33e-05	CcSEcCtD
Bortezomib—Dermatitis—Furosemide—coronary artery disease	9.58e-06	9.33e-05	CcSEcCtD
Bortezomib—Nausea—Captopril—coronary artery disease	9.57e-06	9.32e-05	CcSEcCtD
Bortezomib—Headache—Furosemide—coronary artery disease	9.52e-06	9.27e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Lisinopril—coronary artery disease	9.4e-06	9.15e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Lisinopril—coronary artery disease	9.33e-06	9.08e-05	CcSEcCtD
Bortezomib—Vomiting—Losartan—coronary artery disease	9.33e-06	9.08e-05	CcSEcCtD
Bortezomib—Nausea—Perindopril—coronary artery disease	9.29e-06	9.05e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Ramipril—coronary artery disease	9.27e-06	9.02e-05	CcSEcCtD
Bortezomib—Rash—Losartan—coronary artery disease	9.25e-06	9.01e-05	CcSEcCtD
Bortezomib—Dermatitis—Losartan—coronary artery disease	9.24e-06	9e-05	CcSEcCtD
Bortezomib—Headache—Losartan—coronary artery disease	9.19e-06	8.95e-05	CcSEcCtD
Bortezomib—Urticaria—Lisinopril—coronary artery disease	9.06e-06	8.82e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Timolol—coronary artery disease	9.06e-06	8.82e-05	CcSEcCtD
Bortezomib—Nausea—Furosemide—coronary artery disease	9.03e-06	8.79e-05	CcSEcCtD
Bortezomib—Asthenia—Ramipril—coronary artery disease	9.02e-06	8.79e-05	CcSEcCtD
Bortezomib—Abdominal pain—Lisinopril—coronary artery disease	9.02e-06	8.78e-05	CcSEcCtD
Bortezomib—Body temperature increased—Lisinopril—coronary artery disease	9.02e-06	8.78e-05	CcSEcCtD
Bortezomib—Pruritus—Ramipril—coronary artery disease	8.9e-06	8.67e-05	CcSEcCtD
Bortezomib—Asthenia—Timolol—coronary artery disease	8.82e-06	8.59e-05	CcSEcCtD
Bortezomib—Nausea—Losartan—coronary artery disease	8.71e-06	8.49e-05	CcSEcCtD
Bortezomib—Pruritus—Timolol—coronary artery disease	8.7e-06	8.47e-05	CcSEcCtD
Bortezomib—Diarrhoea—Ramipril—coronary artery disease	8.61e-06	8.38e-05	CcSEcCtD
Bortezomib—Diarrhoea—Timolol—coronary artery disease	8.41e-06	8.19e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Lisinopril—coronary artery disease	8.4e-06	8.18e-05	CcSEcCtD
Bortezomib—Dizziness—Ramipril—coronary artery disease	8.32e-06	8.1e-05	CcSEcCtD
Bortezomib—Asthenia—Lisinopril—coronary artery disease	8.18e-06	7.97e-05	CcSEcCtD
Bortezomib—Dizziness—Timolol—coronary artery disease	8.13e-06	7.92e-05	CcSEcCtD
Bortezomib—Pruritus—Lisinopril—coronary artery disease	8.07e-06	7.86e-05	CcSEcCtD
Bortezomib—Vomiting—Ramipril—coronary artery disease	8e-06	7.79e-05	CcSEcCtD
Bortezomib—Rash—Ramipril—coronary artery disease	7.93e-06	7.72e-05	CcSEcCtD
Bortezomib—Dermatitis—Ramipril—coronary artery disease	7.92e-06	7.72e-05	CcSEcCtD
Bortezomib—Headache—Ramipril—coronary artery disease	7.88e-06	7.67e-05	CcSEcCtD
Bortezomib—Vomiting—Timolol—coronary artery disease	7.82e-06	7.61e-05	CcSEcCtD
Bortezomib—Diarrhoea—Lisinopril—coronary artery disease	7.8e-06	7.6e-05	CcSEcCtD
Bortezomib—Rash—Timolol—coronary artery disease	7.75e-06	7.55e-05	CcSEcCtD
Bortezomib—Dermatitis—Timolol—coronary artery disease	7.75e-06	7.54e-05	CcSEcCtD
Bortezomib—Headache—Timolol—coronary artery disease	7.7e-06	7.5e-05	CcSEcCtD
Bortezomib—Dizziness—Lisinopril—coronary artery disease	7.54e-06	7.35e-05	CcSEcCtD
Bortezomib—Nausea—Ramipril—coronary artery disease	7.47e-06	7.28e-05	CcSEcCtD
Bortezomib—Nausea—Timolol—coronary artery disease	7.3e-06	7.11e-05	CcSEcCtD
Bortezomib—Vomiting—Lisinopril—coronary artery disease	7.25e-06	7.06e-05	CcSEcCtD
Bortezomib—Rash—Lisinopril—coronary artery disease	7.19e-06	7e-05	CcSEcCtD
Bortezomib—Dermatitis—Lisinopril—coronary artery disease	7.19e-06	7e-05	CcSEcCtD
Bortezomib—Headache—Lisinopril—coronary artery disease	7.15e-06	6.96e-05	CcSEcCtD
Bortezomib—Nausea—Lisinopril—coronary artery disease	6.78e-06	6.6e-05	CcSEcCtD
Bortezomib—PSMB2—Immune System—AKT1—coronary artery disease	5.69e-07	6.52e-06	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—AKT1—coronary artery disease	5.69e-07	6.52e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—coronary artery disease	5.68e-07	6.51e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GGT1—coronary artery disease	5.67e-07	6.49e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GOT1—coronary artery disease	5.67e-07	6.49e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GCLC—coronary artery disease	5.66e-07	6.48e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CETP—coronary artery disease	5.66e-07	6.48e-06	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—AKT1—coronary artery disease	5.66e-07	6.48e-06	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—AKT1—coronary artery disease	5.66e-07	6.48e-06	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—AKT1—coronary artery disease	5.66e-07	6.48e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARGC1A—coronary artery disease	5.65e-07	6.48e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—HMOX1—coronary artery disease	5.63e-07	6.45e-06	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—coronary artery disease	5.61e-07	6.43e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—LPL—coronary artery disease	5.61e-07	6.43e-06	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—AKT1—coronary artery disease	5.61e-07	6.43e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SDC1—coronary artery disease	5.6e-07	6.41e-06	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—AKT1—coronary artery disease	5.58e-07	6.39e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PLCB1—coronary artery disease	5.55e-07	6.36e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CAT—coronary artery disease	5.55e-07	6.36e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PLCB3—coronary artery disease	5.52e-07	6.32e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PLCB1—coronary artery disease	5.51e-07	6.31e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GPX1—coronary artery disease	5.48e-07	6.27e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOA5—coronary artery disease	5.46e-07	6.26e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—coronary artery disease	5.4e-07	6.19e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOB—coronary artery disease	5.39e-07	6.17e-06	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PIK3CA—coronary artery disease	5.38e-07	6.17e-06	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PIK3CA—coronary artery disease	5.38e-07	6.17e-06	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PIK3CA—coronary artery disease	5.38e-07	6.17e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ABCA1—coronary artery disease	5.38e-07	6.17e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—P4HB—coronary artery disease	5.36e-07	6.14e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ABCA1—coronary artery disease	5.34e-07	6.11e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CD36—coronary artery disease	5.33e-07	6.11e-06	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PIK3CA—coronary artery disease	5.31e-07	6.08e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TGFB1—coronary artery disease	5.29e-07	6.06e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TGFB1—coronary artery disease	5.29e-07	6.06e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TGFB1—coronary artery disease	5.29e-07	6.06e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PSMB5—coronary artery disease	5.29e-07	6.06e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PSMA6—coronary artery disease	5.29e-07	6.06e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—coronary artery disease	5.28e-07	6.04e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPP2CA—coronary artery disease	5.27e-07	6.03e-06	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—coronary artery disease	5.26e-07	6.03e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PLA2G1B—coronary artery disease	5.26e-07	6.02e-06	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKT1—coronary artery disease	5.25e-07	6.02e-06	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKT1—coronary artery disease	5.25e-07	6.02e-06	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKT1—coronary artery disease	5.25e-07	6.02e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTM1—coronary artery disease	5.24e-07	6.01e-06	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—coronary artery disease	5.24e-07	6e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ALB—coronary artery disease	5.23e-07	5.99e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFB1—coronary artery disease	5.22e-07	5.98e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GGT1—coronary artery disease	5.21e-07	5.97e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GOT1—coronary artery disease	5.21e-07	5.97e-06	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—coronary artery disease	5.21e-07	5.97e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK1—coronary artery disease	5.19e-07	5.94e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK1—coronary artery disease	5.19e-07	5.94e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK1—coronary artery disease	5.19e-07	5.94e-06	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKT1—coronary artery disease	5.18e-07	5.93e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GOT1—coronary artery disease	5.17e-07	5.92e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GGT1—coronary artery disease	5.17e-07	5.92e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CTGF—coronary artery disease	5.16e-07	5.92e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—LPL—coronary artery disease	5.15e-07	5.9e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HMGCR—coronary artery disease	5.12e-07	5.86e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GOT2—coronary artery disease	5.12e-07	5.86e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK1—coronary artery disease	5.12e-07	5.86e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTP1—coronary artery disease	5.09e-07	5.83e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—MTHFR—coronary artery disease	5.05e-07	5.79e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARGC1A—coronary artery disease	5.05e-07	5.78e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—HMOX1—coronary artery disease	5.02e-07	5.75e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GPX1—coronary artery disease	5.02e-07	5.75e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—NOS3—coronary artery disease	5e-07	5.73e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—VCAN—coronary artery disease	4.96e-07	5.68e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CAT—coronary artery disease	4.96e-07	5.68e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALDOA—coronary artery disease	4.92e-07	5.63e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CD36—coronary artery disease	4.89e-07	5.6e-06	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKT1—coronary artery disease	4.85e-07	5.56e-06	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKT1—coronary artery disease	4.83e-07	5.53e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPP2CA—coronary artery disease	4.83e-07	5.53e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOB—coronary artery disease	4.81e-07	5.51e-06	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKT1—coronary artery disease	4.81e-07	5.51e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AGT—coronary artery disease	4.8e-07	5.5e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—DCN—coronary artery disease	4.77e-07	5.47e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PLCB1—coronary artery disease	4.71e-07	5.39e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APOE—coronary artery disease	4.71e-07	5.39e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTP1—coronary artery disease	4.68e-07	5.37e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTM1—coronary artery disease	4.68e-07	5.36e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APOA1—coronary artery disease	4.65e-07	5.33e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALDH2—coronary artery disease	4.64e-07	5.32e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTP1—coronary artery disease	4.64e-07	5.32e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARGC1A—coronary artery disease	4.64e-07	5.32e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—MTHFR—coronary artery disease	4.63e-07	5.31e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—HMOX1—coronary artery disease	4.62e-07	5.29e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—coronary artery disease	4.62e-07	5.29e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARGC1A—coronary artery disease	4.6e-07	5.27e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—LPL—coronary artery disease	4.59e-07	5.26e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—HMOX1—coronary artery disease	4.58e-07	5.25e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—coronary artery disease	4.58e-07	5.24e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ABCA1—coronary artery disease	4.56e-07	5.23e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CAT—coronary artery disease	4.56e-07	5.22e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—LIPC—coronary artery disease	4.53e-07	5.19e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HBA1—coronary artery disease	4.53e-07	5.19e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP2C19—coronary artery disease	4.53e-07	5.19e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3C2A—coronary artery disease	4.53e-07	5.19e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CAT—coronary artery disease	4.52e-07	5.18e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PIK3CA—coronary artery disease	4.5e-07	5.16e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PIK3CA—coronary artery disease	4.5e-07	5.16e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PIK3CA—coronary artery disease	4.5e-07	5.16e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOC3—coronary artery disease	4.5e-07	5.15e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GPX1—coronary artery disease	4.48e-07	5.13e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—LDLR—coronary artery disease	4.47e-07	5.12e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	4.45e-07	5.1e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PIK3CA—coronary artery disease	4.44e-07	5.09e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOB—coronary artery disease	4.42e-07	5.07e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTT1—coronary artery disease	4.42e-07	5.06e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC9A1—coronary artery disease	4.42e-07	5.06e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GGT1—coronary artery disease	4.42e-07	5.06e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GOT1—coronary artery disease	4.42e-07	5.06e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AGT—coronary artery disease	4.4e-07	5.04e-06	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AKT1—coronary artery disease	4.4e-07	5.04e-06	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AKT1—coronary artery disease	4.4e-07	5.04e-06	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AKT1—coronary artery disease	4.4e-07	5.04e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOB—coronary artery disease	4.39e-07	5.03e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CETP—coronary artery disease	4.37e-07	5e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GCLC—coronary artery disease	4.37e-07	5e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CD36—coronary artery disease	4.36e-07	5e-06	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AKT1—coronary artery disease	4.34e-07	4.97e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SDC1—coronary artery disease	4.32e-07	4.95e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOE—coronary artery disease	4.31e-07	4.94e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPP2CA—coronary artery disease	4.31e-07	4.94e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTM1—coronary artery disease	4.3e-07	4.93e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTM1—coronary artery disease	4.27e-07	4.89e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOA1—coronary artery disease	4.26e-07	4.89e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—LPL—coronary artery disease	4.22e-07	4.84e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—LPL—coronary artery disease	4.19e-07	4.8e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—MTHFR—coronary artery disease	4.14e-07	4.74e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GPX1—coronary artery disease	4.12e-07	4.72e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARG—coronary artery disease	4.1e-07	4.7e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GPX1—coronary artery disease	4.09e-07	4.68e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	4.08e-07	4.68e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PSMA6—coronary artery disease	4.08e-07	4.67e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PSMB5—coronary artery disease	4.08e-07	4.67e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—POMC—coronary artery disease	4.04e-07	4.63e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CD36—coronary artery disease	4.01e-07	4.6e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—coronary artery disease	3.99e-07	4.57e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—coronary artery disease	3.99e-07	4.57e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—coronary artery disease	3.99e-07	4.57e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CTGF—coronary artery disease	3.99e-07	4.57e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CD36—coronary artery disease	3.98e-07	4.56e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTP1—coronary artery disease	3.97e-07	4.55e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPP2CA—coronary artery disease	3.96e-07	4.54e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HMGCR—coronary artery disease	3.95e-07	4.52e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GOT2—coronary artery disease	3.95e-07	4.52e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARGC1A—coronary artery disease	3.93e-07	4.5e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—coronary artery disease	3.93e-07	4.5e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPP2CA—coronary artery disease	3.93e-07	4.5e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AGT—coronary artery disease	3.93e-07	4.5e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HMOX1—coronary artery disease	3.91e-07	4.48e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CAT—coronary artery disease	3.86e-07	4.42e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOE—coronary artery disease	3.85e-07	4.41e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOA1—coronary artery disease	3.81e-07	4.36e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—MTHFR—coronary artery disease	3.8e-07	4.36e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—MTHFR—coronary artery disease	3.77e-07	4.32e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARG—coronary artery disease	3.76e-07	4.3e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOB—coronary artery disease	3.75e-07	4.29e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—POMC—coronary artery disease	3.71e-07	4.25e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ALB—coronary artery disease	3.69e-07	4.22e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKT1—coronary artery disease	3.68e-07	4.21e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKT1—coronary artery disease	3.68e-07	4.21e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKT1—coronary artery disease	3.68e-07	4.21e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTM1—coronary artery disease	3.65e-07	4.18e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	3.64e-07	4.18e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PLCB1—coronary artery disease	3.63e-07	4.16e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKT1—coronary artery disease	3.63e-07	4.15e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AGT—coronary artery disease	3.61e-07	4.14e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AGT—coronary artery disease	3.58e-07	4.1e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—LPL—coronary artery disease	3.58e-07	4.1e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOE—coronary artery disease	3.54e-07	4.06e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—NOS3—coronary artery disease	3.52e-07	4.04e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCA1—coronary artery disease	3.52e-07	4.03e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOE—coronary artery disease	3.51e-07	4.02e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOA1—coronary artery disease	3.5e-07	4.01e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GPX1—coronary artery disease	3.49e-07	4e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOA1—coronary artery disease	3.47e-07	3.98e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GGT1—coronary artery disease	3.41e-07	3.91e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GOT1—coronary artery disease	3.41e-07	3.91e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CD36—coronary artery disease	3.4e-07	3.9e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ALB—coronary artery disease	3.38e-07	3.87e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPP2CA—coronary artery disease	3.36e-07	3.85e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARG—coronary artery disease	3.35e-07	3.84e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	3.32e-07	3.81e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—POMC—coronary artery disease	3.31e-07	3.79e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NOS3—coronary artery disease	3.23e-07	3.7e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—coronary artery disease	3.22e-07	3.69e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MTHFR—coronary artery disease	3.22e-07	3.69e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARG—coronary artery disease	3.08e-07	3.53e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTP1—coronary artery disease	3.06e-07	3.51e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AGT—coronary artery disease	3.06e-07	3.51e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARG—coronary artery disease	3.06e-07	3.5e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—POMC—coronary artery disease	3.04e-07	3.49e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARGC1A—coronary artery disease	3.03e-07	3.48e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HMOX1—coronary artery disease	3.02e-07	3.46e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—POMC—coronary artery disease	3.02e-07	3.46e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALB—coronary artery disease	3.02e-07	3.45e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOE—coronary artery disease	3e-07	3.44e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CAT—coronary artery disease	2.98e-07	3.41e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOA1—coronary artery disease	2.97e-07	3.4e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—coronary artery disease	2.96e-07	3.39e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOB—coronary artery disease	2.89e-07	3.31e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NOS3—coronary artery disease	2.88e-07	3.3e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	2.84e-07	3.25e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CA—coronary artery disease	2.82e-07	3.23e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTM1—coronary artery disease	2.81e-07	3.22e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALB—coronary artery disease	2.77e-07	3.18e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—LPL—coronary artery disease	2.76e-07	3.16e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALB—coronary artery disease	2.75e-07	3.15e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GPX1—coronary artery disease	2.69e-07	3.09e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NOS3—coronary artery disease	2.65e-07	3.04e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—coronary artery disease	2.64e-07	3.02e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NOS3—coronary artery disease	2.63e-07	3.01e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CD36—coronary artery disease	2.62e-07	3.01e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARG—coronary artery disease	2.61e-07	2.99e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPP2CA—coronary artery disease	2.59e-07	2.97e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—POMC—coronary artery disease	2.58e-07	2.95e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MTHFR—coronary artery disease	2.49e-07	2.85e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—coronary artery disease	2.43e-07	2.78e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—coronary artery disease	2.41e-07	2.76e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AGT—coronary artery disease	2.36e-07	2.71e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALB—coronary artery disease	2.35e-07	2.69e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOE—coronary artery disease	2.32e-07	2.65e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AKT1—coronary artery disease	2.3e-07	2.63e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOA1—coronary artery disease	2.29e-07	2.62e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NOS3—coronary artery disease	2.25e-07	2.57e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—coronary artery disease	2.06e-07	2.35e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARG—coronary artery disease	2.02e-07	2.31e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—POMC—coronary artery disease	1.99e-07	2.28e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CA—coronary artery disease	1.98e-07	2.27e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CA—coronary artery disease	1.82e-07	2.08e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALB—coronary artery disease	1.81e-07	2.08e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NOS3—coronary artery disease	1.73e-07	1.99e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CA—coronary artery disease	1.62e-07	1.86e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AKT1—coronary artery disease	1.62e-07	1.86e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—coronary artery disease	1.59e-07	1.82e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CA—coronary artery disease	1.49e-07	1.71e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKT1—coronary artery disease	1.49e-07	1.7e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CA—coronary artery disease	1.48e-07	1.7e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKT1—coronary artery disease	1.33e-07	1.52e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CA—coronary artery disease	1.26e-07	1.45e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKT1—coronary artery disease	1.22e-07	1.4e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKT1—coronary artery disease	1.21e-07	1.39e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKT1—coronary artery disease	1.03e-07	1.18e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CA—coronary artery disease	9.76e-08	1.12e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKT1—coronary artery disease	7.97e-08	9.13e-07	CbGpPWpGaD
